Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25686999 | 0.79 | SLC34A1 (0.33) | MAPK14CYP19A1MEN1KMT2A | |
| SCHEMBL25687000 | 0.79 | SLC34A1 (0.33) | MAPK14CYP19A1MEN1KMT2A | |
| SCHEMBL30007885 | 0.79 | SLC34A1 (0.33) | MAPK14CYP19A1MEN1KMT2A | |
| SCHEMBL23958787 | 0.79 | SLC34A1 (0.33) | MAPK14CYP19A1MEN1KMT2A | |
| SCHEMBL30006977 | 0.77 | SLC34A1 (0.35) | MAPK14DPP4CYP19A1 | |
| SCHEMBL25686861 | 0.77 | SLC34A1 (0.35) | MAPK14DPP4CYP19A1 | |
| SCHEMBL25279827 | 0.75 | SLC34A1 (0.32) | MAPK14 | |
| SCHEMBL23958790 | 0.69 | CFTR (0.34) | DPP4L3MBTL1 | |
| SCHEMBL23958632 | 0.69 | CFTR (0.34) | DPP4L3MBTL1 | |
| SCHEMBL25686955 | 0.69 | CFTR (0.34) | DPP4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | MAPK14 2142/4885EGFR 3946/4885DPP4 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.